These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 23516309)

  • 21. Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients.
    Zinzani PL; Rigacci L; Stefoni V; Broccoli A; Puccini B; Castagnoli A; Vaggelli L; Zanoni L; Argnani L; Baccarani M; Fanti S
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):4-12. PubMed ID: 21894546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive value on advance hodgkin lymphoma treatment outcome of end-of treatment FDG PET/CT in the HD0607 clinical trial.
    Biggi A; Chauvie S; Fallanca F; Guerra L; Bergesio F; Menga M; Bianchi A; Gregianin M; Chiaravalloti A; Schillaci O; Pavoni C; Patti C; Picardi M; Romano A; Schiavotto C; Sorasio R; Viviani S; La Nasa G; Trentin L; Rambaldi A; Gallamini A
    Hematol Oncol; 2023 Aug; 41(3):415-423. PubMed ID: 36534947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.
    Mesguich C; Cazeau AL; Bouabdallah K; Soubeyran P; Guyot M; Milpied N; Bordenave L; Hindié E
    Br J Haematol; 2016 Nov; 175(4):652-660. PubMed ID: 27539369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma.
    Picardi M; Fonti R; Della Pepa R; Giordano C; Pugliese N; Nicolai E; Salvatore M; Mainolfi C; Venetucci P; Rascato MG; Cappuccio I; Mascolo M; Vigliar E; Troncone G; Del Vecchio S; Pane F
    Eur J Cancer; 2020 Jun; 132():85-97. PubMed ID: 32334339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
    Hutchings M; Kostakoglu L; Zaucha JM; Malkowski B; Biggi A; Danielewicz I; Loft A; Specht L; Lamonica D; Czuczman MS; Nanni C; Zinzani PL; Diehl L; Stern R; Coleman M
    J Clin Oncol; 2014 Sep; 32(25):2705-11. PubMed ID: 25071108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CT.
    Lynch RC; Advani RH
    Am Soc Clin Oncol Educ Book; 2016; 35():e376-85. PubMed ID: 27249744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study.
    Barrington SF; Kirkwood AA; Franceschetto A; Fulham MJ; Roberts TH; Almquist H; Brun E; Hjorthaug K; Viney ZN; Pike LC; Federico M; Luminari S; Radford J; Trotman J; Fosså A; Berkahn L; Molin D; D'Amore F; Sinclair DA; Smith P; O'Doherty MJ; Stevens L; Johnson PW
    Blood; 2016 Mar; 127(12):1531-8. PubMed ID: 26747247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Posttreatment PET/CT Rather Than Interim PET/CT Using Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma: A Prospective Study Comparing PET/CT with Conventional Imaging.
    Bakhshi S; Bhethanabhotla S; Kumar R; Agarwal K; Sharma P; Thulkar S; Malhotra A; Dhawan D; Vishnubhatla S
    J Nucl Med; 2017 Apr; 58(4):577-583. PubMed ID: 27754902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence.
    Seshachalam A; Karpurmath SV; Rathnam K; Raman SG; Janarthinakani M; Prasad K; Patil C; Anoop P; Reddy N; Anumula SK; Roopa SP; Golamari KR; Danthala M; Gunari P; Malipatil B; Rangarajan B; Udupa KS; Nandennavar M; Niraimathi K; Shewade HD
    J Glob Oncol; 2019 Nov; 5():1-13. PubMed ID: 31834832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Standard therapies versus novel therapies in Hodgkin lymphoma.
    Gallamini A; Di Raimondo F; La Nasa G; Romano A; Borra A; Greco M
    Immunol Lett; 2013; 155(1-2):56-9. PubMed ID: 24140162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.
    Raemaekers JM; André MP; Federico M; Girinsky T; Oumedaly R; Brusamolino E; Brice P; Fermé C; van der Maazen R; Gotti M; Bouabdallah R; Sebban CJ; Lievens Y; Re A; Stamatoullas A; Morschhauser F; Lugtenburg PJ; Abruzzese E; Olivier P; Casasnovas RO; van Imhoff G; Raveloarivahy T; Bellei M; van der Borght T; Bardet S; Versari A; Hutchings M; Meignan M; Fortpied C
    J Clin Oncol; 2014 Apr; 32(12):1188-94. PubMed ID: 24637998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined prognostic role of TARC and interim
    Husi K; Pinczés LI; Fejes Z; Nagy B; Illés Á; Miltényi Z
    Hell J Nucl Med; 2022; 25(2):125-131. PubMed ID: 35913858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of
    Isik EG; Kuyumcu S; Kebudi R; Sanli Y; Karakas Z; Cakir FB; Unal SN
    Ann Nucl Med; 2017 Nov; 31(9):660-668. PubMed ID: 28741053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment strategy for newly diagnosed classical Hodgkin lymphoma: current achievements using interim PET-guided therapy].
    Kusumoto S
    Rinsho Ketsueki; 2020; 61(9):1244-1251. PubMed ID: 33162522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDG-PET for Early Response Assessment in Lymphomas: Part 1-Hodgkin Lymphoma.
    Cheson BD; Kostakoglu L
    Oncology (Williston Park); 2017 Jan; 31(1):45-9. PubMed ID: 28090622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin's Lymphoma.
    Al-Ibraheem A; Anwer F; Juweid ME; Shagera QA; Khalaf AN; Obeidat S; Mansour A; Ma'koseh M; Halahleh K; Jaradat I; Almasri N; Mansour A
    Sci Rep; 2022 Oct; 12(1):17702. PubMed ID: 36271128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inter-Reader Reliability of Early FDG-PET/CT Response Assessment Using the Deauville Scale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin's Lymphoma.
    Kluge R; Chavdarova L; Hoffmann M; Kobe C; Malkowski B; Montravers F; Kurch L; Georgi T; Dietlein M; Wallace WH; Karlen J; Fernández-Teijeiro A; Cepelova M; Wilson L; Bergstraesser E; Sabri O; Mauz-Körholz C; Körholz D; Hasenclever D
    PLoS One; 2016; 11(3):e0149072. PubMed ID: 26963909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy.
    Sher DJ; Mauch PM; Van Den Abbeele A; LaCasce AS; Czerminski J; Ng AK
    Ann Oncol; 2009 Nov; 20(11):1848-53. PubMed ID: 19541793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of escalating therapy with brentuximab vedotin-AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD.
    Martínez C; Carcelero E; Gutiérrez A; Sancho E; Martí-Tutusaus JM; Magnano L; Mozas P; Fernández-Avilés F; Antelo MG; Setoain X; Rodríguez S; Esteve J
    Hematol Oncol; 2024 Sep; 42(5):e3299. PubMed ID: 39132926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States.
    Winter A; Liu N; Surinach A; Fanale M; Yu KS; Narkhede M
    Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):527-534. PubMed ID: 37121857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.